Unresectable hepatocellular carcinoma : MR imaging after intraarterial therapy. part ii. response stratification using volumetric functional criteria after intraarterial therapy

Radiology

Volumn 268, Issue 2, 2013, Pages 431-439

  Bonekamp, Susanne ^a   Halappa, Vivek Gowdra ^a   Geschwind, Jean François H ^a   Li, Zhen ^a   Corona Villalobos, Celia Pamela ^a   Reyes, Diane ^a   Bhagat, Nikhil ^a   Cosgrove, David P ^b,c   Pawlik, Timothy M ^a   Mezey, Esteban ^a   Eng, John ^a   Kamel, Ihab R ^a  

^a Department of Radiology ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN;

ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONTROLLED STUDY; DEATH; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ENHANCEMENT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; VOLUMETRY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880655276     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121637     Document Type: Article

References (41)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-1491.
2. Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multicenter, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation: HeiLivCa [ISRCTN24081794] [abstr]. BMC Cancer 2008;8:349.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37(2):429-442.
4. Memon K, Kulik L, Lewandowski RJ, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. J Hepatol 2012;56(5):1112-1120.
5. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012;57(1):101-107.
6. Kim BK, Ahn SH, Seong JS, et al. Early a-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 2011;31(3):369-376.
7. Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011;16(9):1270-1279.
8. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009;27(3):446-452.
9. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27(34):5734-5742.
10. Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35(11):1343-1350.
11. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: Diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009;193(4):1044-1052.
12. Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141(2):526-535.e2.
13. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: Assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010;31(2):348-355.
14. Chung JC, Naik NK, Lewandowski RJ, et al. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 2010;16(25):3161-3167.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
17. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35(3):421-430.
18. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: Practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
19. Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010;49(4):509-514.
20. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616-623.
21. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
22. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102(15):5524-5529.
23. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: Response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrastenhanced MR imaging data. Radiology 2011;260(3):752-761.
24. Padhani AR, Liu G, Koh DM, et al. Diffusionweighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia 2009;11(2):102-125.
25. Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: Effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003;26(2):111-117.
26. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: Initial experience in the United States. Cancer J 2009;15(6):526-532.
27. Duke E, Deng J, Ibrahim SM, et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010;21(4):515-521.
28. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303(11):1062-1069.
29. Bonekamp S, Li Z, Geschwind JFH, et al. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. I. Identification and validation of volumetric functional response criteria. Radiology 2013;268(2):420-430.
30. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? a validation study of old and new models. Radiology 2012;262(2):708-718.
31. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979.
32. Vilgrain V. Advancement in HCC imaging: Diagnosis, staging and treatment efficacy assessments-hepatocellular carcinoma: Imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 2010;17(4):374-379.
33. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
34. Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010;33(6):1143-1152.
35. Yu JS, Kim JH, Chung JJ, Kim KW. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 2009;30(1):153-160.
36. Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The diffusionweighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: A pilot study. Eur Radiol 2011;21(2):281-290.
37. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2):466-473.
38. Assumpcao L, Choti M, Pawlik TM, Gecshwind JF, Kamel IR. Functional MR imaging as a new paradigm for image guidance. Abdom Imaging 2009;34(6):675-685.
39. Braren R, Altomonte J, Settles M, et al. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol 2011;55(5):1034-1040.
40. Jin B, Wang D, Lewandowski RJ, et al. Chemoembolization endpoints: Effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011;196(4):919-928.
41. Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: Comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255(3):955-965.